BioSpace News Archive

New data from the HARMONIE Phase 3b clinical trial show an 83.21% reduction in hospitalizations due to RSV-related LRTD in infants under 12 months of age who received a single dose of nirsevimab, compared to infants who received no RSV intervention.1.

Celcuity Inc. announced that updated results from a Phase 1b trial evaluating gedatolisib, a pan-PI3K/mTOR inhibitor, in combination with palbociclib, a CDK4/6 inhibitor, and letrozole, an aromatase inhibitor, were presented at the 2023 European Society for Medical Oncology Breast Cancer Annual Congress in Berlin, Germany.

Reviva Pharmaceuticals Holdings, Inc. announced that it will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023.

Bio-Path Holdings, Inc. announced its financial results for the first quarter ended March 31, 2023 and provided an update on recent corporate developments.

Decibel Therapeutics announced approval of its Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate.

Humacyte, Inc. and Oberland Capital Management LLC announced a $150 million, capped funding arrangement based on future revenues of Humacyte’s Human Acellular Vessel™, as well as a $10 million equity investment option.

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the first quarter ended March 31, 2023, and highlighted recent corporate accomplishments.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today reported financial results and business highlights for the first quarter ended March 31, 2023.

Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners, today reported financial results for the three months ended March 31, 2023.

Protagonist Therapeutics reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235), presented by Janssen and co-authored with Protagonist, as an oral presentation at the International Societies for Investigative Dermatology (ISID) 2023 meeting in Tokyo, Japan.